Biovista signs EU-IMI2 research agreement to advance neurotoxicity de-risking in preclinical drug discovery

March 15, 2019Announcements

Biovista is pleased to announce the signature of a grant agreement within the remit of the EU’s Innovative Medicines Initiative. Starting in March 2019, the 3.5 year “NeuroDeRisk” project aims to advance the industry’s ability to tackle three of the most challenging adverse effects: seizures, psychological/psychiatric changes, and peripheral neuropathies. Together with EFPIA members Sanofi, … Read More